Autoimmune polyendocrine syndrome secondary prevention: Difference between revisions
Akshun Kalia (talk | contribs) |
Akshun Kalia (talk | contribs) |
||
| Line 12: | Line 12: | ||
==Secondary Prevention== | ==Secondary Prevention== | ||
Effective measures for the secondary prevention of autoimmune polyendocrine syndrome (APS) include: | Effective measures for the secondary prevention of autoimmune polyendocrine syndrome (APS) include: | ||
*Patient education: Patient education is an important aspect in early diagnosis and management of APS. In APS the time interval between involvement of one endocrine | *Patient education: Patient education is an important aspect in early diagnosis and management of APS. In APS the time interval between involvement of one endocrine tissue to other endocrine tissue may take years. For example, patients with APS type 1 develops mucocutaneous candidiasis in infancy and it may take upto five years for them to develop hypoparathyroidism. Patients should also be informed about symptoms of other disorders for which they are at high risk such as Addison's disease or diabetes mellitus. | ||
*Patients with type 1 and type 2 APS should be screened at an interval of 6 to 12 months for development of other endocrine/non-endocrine disorders. | *Patients with type 1 and type 2 APS should be screened at an interval of 6 to 12 months for development of other endocrine/non-endocrine disorders. | ||
**If autoantibodies are present without the associated disease, functional testing is indicated. | **If autoantibodies are present without the associated disease, functional testing is indicated. | ||
Revision as of 18:42, 28 September 2017
|
Autoimmune polyendocrine syndrome Microchapters |
|
Differentiating Autoimmune polyendocrine syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Autoimmune polyendocrine syndrome secondary prevention On the Web |
|
American Roentgen Ray Society Images of Autoimmune polyendocrine syndrome secondary prevention |
|
FDA on Autoimmune polyendocrine syndrome secondary prevention |
|
CDC on Autoimmune polyendocrine syndrome secondary prevention |
|
Autoimmune polyendocrine syndrome secondary prevention in the news |
|
Blogs on Autoimmune polyendocrine syndrome secondary prevention |
|
Directions to Hospitals Treating Autoimmune polyendocrine syndrome |
|
Risk calculators and risk factors for Autoimmune polyendocrine syndrome secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
There are no established measures for the secondary prevention of [disease name].
OR
Effective measures for the secondary prevention of [disease name] include [strategy 1], [strategy 2], and [strategy 3].
Secondary Prevention
Effective measures for the secondary prevention of autoimmune polyendocrine syndrome (APS) include:
- Patient education: Patient education is an important aspect in early diagnosis and management of APS. In APS the time interval between involvement of one endocrine tissue to other endocrine tissue may take years. For example, patients with APS type 1 develops mucocutaneous candidiasis in infancy and it may take upto five years for them to develop hypoparathyroidism. Patients should also be informed about symptoms of other disorders for which they are at high risk such as Addison's disease or diabetes mellitus.
- Patients with type 1 and type 2 APS should be screened at an interval of 6 to 12 months for development of other endocrine/non-endocrine disorders.
- If autoantibodies are present without the associated disease, functional testing is indicated.
- Patients with antibodies against 21-hydroxylase should be monitored annually for ACTH levels, morning (8 am) cortisol levels, and cosyntropin stimulation testing. The time interval between testing may vary depending upon the signs and symptoms of the disease.